Skip to main content
. 2024 Feb 5;10(1):e003596. doi: 10.1136/rmdopen-2023-003596

Figure 1.

Figure 1

Change from baseline over 52 weeks in DAS28-ESR in patients with moderate-to-severe rheumatoid arthritis initially randomised to MSB11456 or EU-approved tocilizumab and in those rerandomised from EU-approved tocilizumab to MSB11456 at week 24, ITT analysis set. DAS28-ESR, Disease Activity Score-28 Joint erythrocyte sedimentation rate; EU, European Union; ITT, intention to treat.